Checkmate Pharmaceuticals, Inc. Stock News

Checkmate Pharmaceuticals (NASDAQ:CMPI) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Tuesday, Zacks.com reports. The brokerage currently has a $4.50 price target on the stock. Zacks Investment Researchs price target would indicate a potential upside of 20.32% from the stocks previous close. According []

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities. The Check

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary tec

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary te

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary te

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like d

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary